Meeting
2016 ASCO Annual Meeting
PRECIOUS: A randomized, open-label phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients who were previously treated with pertuzumab, trastuzumab, and chemotherapy.
Authors
Yutaka Yamamoto
Kumamoto University, Graduate School of Medical Sciences, Kumamoto, Japan
Yutaka Yamamoto , Hiroji Iwata , Takayuki Ueno , Masahiro Kashiwaba , Naruto Taira , Masato Takahashi , Hiroshi Tada , Koichiro Tsugawa , Tatsuya Toyama , Naoki Niikura , Fumikata Hara , Tomomi Fujisawa , Tetsuhiro Yoshinami , Shigehira Saji , Toshimi Takano , Norikazu Masuda , Satoshi Morita , Masakazu Toi , Shinji Ohno
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Clinical Trial Registration Number
NCT02514681
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS636)
DOI
10.1200/JCO.2016.34.15_suppl.TPS636
Abstract #
TPS636
Poster Bd #
112b
Abstract Disclosures
Similar Posters
First Author: Kathy Miller
First Author: Kathy Miller
Poster
2016 ASCO Annual Meeting
SOPHIA: A phase 3, randomized study of margetuximab (M) plus chemotherapy (CTX) vs trastuzumab (T) plus CTX in the treatment of patients with HER2+ metastatic breast cancer (MBC).
First Author: Hope S. Rugo
Poster
2023 ASCO Annual Meeting
Pertuzumab retreatment in patients with HER2-positive locally advanced/metastatic breast cancer: Overall survival results of a phase III randomized trial (JBCRG-M05: PRECIOUS).
First Author: Yutaka Yamamoto